The main clinical use of plasma C-peptide assay is in the differentiation of endogenous hyperinsulinism from exogenous (factitious) hyperinsulinism. In infants with functional hyperinsulinism, plasma C-peptide levels may reveal inappropriate insulin secretionwhen insulin assays themselves fail to do so because of insulin extraction by the liver.
